Published in Neuron on November 05, 2014
Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. Brain (2015) 1.46
Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis. Nat Commun (2016) 0.86
An Alzheimer's Disease-Derived Biomarker Signature Identifies Parkinson's Disease Patients with Dementia. PLoS One (2016) 0.81
Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease. Ann Clin Transl Neurol (2016) 0.79
Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease. Mov Disord (2016) 0.77
The Role of Metabolomics in Brain Metabolism Research. J Neuroimmune Pharmacol (2015) 0.77
α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med (2017) 0.76
Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson's Disease Patients. PLoS One (2015) 0.76
Analysis of blood-based gene expression in idiopathic Parkinson disease. Neurology (2017) 0.75
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science (1990) 35.96
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry (1992) 33.67
Complement factor H polymorphism in age-related macular degeneration. Science (2005) 31.10
In vitro selection of RNA molecules that bind specific ligands. Nature (1990) 30.19
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Common genetic variation and human traits. N Engl J Med (2009) 21.03
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
Complement factor H variant increases the risk of age-related macular degeneration. Science (2005) 17.95
Complement factor H polymorphism and age-related macular degeneration. Science (2005) 17.79
Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Infect Dis (2009) 16.51
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther (2001) 14.78
Translational and clinical science--time for a new vision. N Engl J Med (2005) 14.65
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res (2013) 14.23
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain (1991) 8.16
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am (2005) 7.26
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A (2009) 6.87
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology (2006) 6.86
Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 6.84
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (2012) 6.66
Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom Rev (2005) 5.98
The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord (2008) 5.72
Human metabolic phenotype diversity and its association with diet and blood pressure. Nature (2008) 5.41
Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol (2004) 5.01
A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat Biotechnol (2001) 4.66
The cancer biomarker problem. Nature (2008) 4.64
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature (2009) 4.43
Progress and promise of genome-wide association studies for human complex trait genetics. Genetics (2010) 3.81
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology (2010) 3.70
Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology (2007) 3.62
Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology (2008) 3.62
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology (1996) 3.48
Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med (2014) 3.45
Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol (2009) 3.34
Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology (2001) 3.25
Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med (2013) 3.25
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol (2011) 3.12
Plasma urate and risk of Parkinson's disease. Am J Epidemiol (2007) 3.06
High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology (2009) 3.04
Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A (2007) 3.03
The role of radiotracer imaging in Parkinson disease. Neurology (2005) 3.02
MicroRNAs: novel biomarkers for human cancer. Clin Chem (2009) 2.97
Assay of plasma insulin in human subjects by immunological methods. Nature (1959) 2.87
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Metabolic phenotyping in health and disease. Cell (2008) 2.80
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79
Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2006) 2.77
Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol (2008) 2.73
Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol (2010) 2.73
CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology (2010) 2.67
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
Biomarker modeling of Alzheimer's disease. Neuron (2013) 2.51
Serum uric acid levels and the risk of Parkinson disease. Ann Neurol (2005) 2.47
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2013) 2.32
Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol (2008) 2.31
Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun (2006) 2.27
Accuracy of clinical diagnosis in parkinsonism--a prospective study. Can J Neurol Sci (1991) 2.26
Advances in the genetics of Parkinson disease. Nat Rev Neurol (2013) 2.21
Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol (2010) 2.20
Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology (2008) 2.13
Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J Intern Med (2012) 2.13
The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology (2003) 2.11
Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist (2008) 2.10
Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain (2008) 2.10
Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease. Am J Epidemiol (1996) 2.08
Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett (2000) 1.98
The coming crisis: obtaining care for the growing burden of neurodegenerative conditions. Neurology (2013) 1.98
Antibody-based protein multiplex platforms: technical and operational challenges. Clin Chem (2009) 1.95
Dementia and survival in Parkinson disease: a 12-year population study. Neurology (2008) 1.86
Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol (2012) 1.86
Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement (2011) 1.85
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol (2013) 1.83
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci (2013) 1.82
The current and projected economic burden of Parkinson's disease in the United States. Mov Disord (2013) 1.80
Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci (2000) 1.79
Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS One (2010) 1.72
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord (2010) 1.71
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol (2011) 1.68
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study. Mov Disord (2012) 1.60
A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch Neurol (1992) 1.59
Inner retinal layer thinning in Parkinson disease. Arch Ophthalmol (2009) 1.58
CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry (2010) 1.55
Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord (2009) 1.54
EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. Eur J Neurol (2013) 1.52